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Protocol
ABSTRACT
Introduction Cigarette smoking is one of the leading 
causes of early death in the UK and worldwide. Public 
health guidance recommends the use of varenicline, 
bupropion and nicotine replacement therapy (NRT) as 
smoking cessation aids in the UK. Additionally, the first 
electronic cigarette has been licensed for use as a 
smoking cessation medicine. However, there are ongoing 
concerns about the safety of these medicines. We present 
a protocol for a systematic review and network meta-
analysis (NMA) to determine how these smoking cessation 
medicines compare to each other with respect to their 
neuropsychiatric safety in adult smokers. Secondary aims 
include updating the evidence regarding the effectiveness 
and cardiovascular safety of these medicines for use in a 
cost-effectiveness analysis.
Methods and analysis We will include randomised 
controlled trials and observational studies with control 
groups comparing monotherapy with varenicline, 
bupropion, NRT or electronic cigarette and combination 
therapies to each other, placebo or usual care. The 
primary composite safety outcome will be serious adverse 
events, defined as events that resulted in death, were 
life threatening, required hospitalisation or resulted 
in significant disability or congenital/birth defect. The 
preferred effectiveness outcome will be sustained 
smoking cessation defined as abstinence for a minimum 
of 6 months as determined by biochemical validation. 
We will include trials identified by previous reviews and 
search relevant databases for newly published trials as 
well as contacting study authors to identify unpublished 
information. We will conduct fixed-effect and random-
effect meta-analyses for each pairwise comparison of 
treatments and outcome; where these estimates differ, 
we will consider reasons for heterogeneity, quantified 
using the between-study variance (τ2). For each outcome, 
we will construct a NMA in a Bayesian framework which 
will be compared with the pair-wise results, allowing us 
to rank treatments. The effectiveness estimates from the 
NMA will be entered into a probabilistic economic model.
Ethics and dissemination Ethics approval is not 
required for this evidence synthesis study as it involves 
analysis of secondary data from randomised controlled 
trials and observational studies. The review will make an 
important contribution to the knowledge base around the 
effectiveness, safety and cost-effectiveness of smoking 
cessation medicines. Results will be disseminated to the 
general public, healthcare practitioners and clinicians, 
academics, industry and policy makers.
PROSPERO registration number CRD42016041302.
InTroducTIon
Cigarette smoking is one of the leading causes 
of early death in the UK and worldwide.1 2 
Each year, more than 100 000 people will die 
in the UK from smoking related diseases.3 
The National Institute for Health and Care 
Excellence (NICE) public health guidance 
Strengths and limitations of this study
 ► This study will be the first comprehensive review of 
the neuropsychiatric safety of smoking cessation 
medicines in relation to each other and will include 
randomised controlled trials of any duration as 
well as observational studies with control groups. 
Including observational studies will allow us to 
identify sufficient data for the network meta-
analysis and improve the precision of estimates of 
adverse events.
 ► This study will include trials of combined therapies 
of smoking cessation medicines, not included in 
previous network meta-analyses, as the analysis of 
both safety and efficacy data on coprescribing could 
be of important to regulators.
 ► This study will produce updated cost-effectiveness 
analyses to estimate which smoking cessation 
medicine is the most cost-effective in UK settings.
 ► We will use the Cochrane tool for assessing the risk 
of bias and consider using the risk of bias in non-
randomised studies of interventions tool to assess 
the risk of bias in randomised controlled trials and 
observational studies, respectively.
 ► This study will be limited to products licensed for 
use as smoking cessation aids in the UK.
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(published in 2008) recommends the use of three medi-
cines, varenicline, bupropion and nicotine replacement 
therapy (NRT), as aids to quitting smoking in the UK.4 
Additionally, in the late 2015, the Medicines and Health-
care Products Regulatory Agency (MHRA) approved the 
use of British American Tobacco’s electronic cigarette 
‘e-Voke’ as a smoking cessation medicine.5 Since the 
publication of the original NICE guidance, there have 
been ongoing concerns about the safety of the smoking 
cessation medicines, with particular respect to the neuro-
psychiatric safety of varenicline. Severe safety warnings 
(black triangle and black box warnings) regarding a 
potential increased risk of serious neuropsychiatric 
adverse events (depression, suicidal ideation and suicidal 
behaviour) in patients prescribed these medicines have 
previously been issued by regulatory agencies such as 
the MHRA in the UK and the Food and Drug Adminis-
tration (FDA) in the USA.6 7 These safety warnings were 
based on spontaneous reports to the UK Yellow Card 
Scheme and the FDA Adverse Events Reporting Data-
base. Previous research into the neuropsychiatric safety 
of these medicines has provided inconsistent findings, 
adding to the debate.8 In April 2016, the results of Evalu-
ating Adverse Events in a Global Smoking Cessation Study 
(EAGLES) trial,9 a randomised controlled trial (RCT) 
that randomised 8144 smokers to receive varenicline, 
transdermal NRT patch, bupropion or placebo, were 
published. The trial’s findings provided strong evidence 
that both varenicline and bupropion do not cause an 
increase in neuropsychiatric adverse events relative to 
nicotine patch or placebo. Subsequently, the European 
Medicines Agency lifted the warning about possible 
suicidal risks from varenicline in April 2016,10 followed 
by the FDA’s decision to remove the black box warnings 
on varenicline’s labelling in December 2016. While the 
EAGLES trial may be the largest global clinical trial of 
smoking cessation medicines, its sample size is limited 
relative to much larger observational cohort studies.11 12 
Therefore, synthesising these findings with those of other 
RCTs, as well as synthesising the results of observational 
studies, will offer a more comprehensive review of the 
neuropsychiatric safety of smoking cessation medicines. 
With the MHRA’s licensing of the first electronic cigarette 
as a smoking cessation medicine, and given the popularity 
of electronic cigarettes with an estimated 2.8 million adult 
users in Great Britain,13 it is important to review their 
effectiveness as a smoking cessation aid as well as their 
safety.
The health benefits of smoking cessation have been 
well documented. Varenicline has been shown to be 
the most clinically effective monotherapy for long-term 
smoking abstinence (>6 months).14 However, the number 
of prescription items of varenicline dispensed in England 
decreased by 25% from a peak of approximately one 
million prescriptions in 2011 to almost 742 000 prescrip-
tions in 2013,15 possibly reflecting ongoing fears among 
prescribers and patients regarding varenicline’s neuro-
psychiatric safety. It is important for patients, prescribers 
and regulators to know how smoking cessation medicines 
compare with each other, with particular respect to their 
neuropsychiatric safety, to enable smokers wanting to 
quit and their healthcare professionals to make informed 
decisions about the risks and benefits of the different 
pharmacological treatments. To date, there has been no 
comprehensive analysis of the neuropsychiatric safety 
of the smoking cessation medicines; previous system-
atic reviews have focused on comparisons of varenicline 
with placebo.16–18 In addition, the cost-effectiveness of 
these medicines in UK settings has not been investigated 
using the most up-to-date evidence. These analyses are 
important to inform the overall risk–benefit evaluation of 
the different smoking cessation medicines.
The ongoing debate regarding the neuropsychiatric 
safety of drugs for smoking cessation among drug regula-
tors, researchers, prescribers and patients may be due to 
the inconsistent research findings in this area.8 Whereas 
studies without control groups (such as those using adverse 
event reporting data and case studies)19–21 have reported 
increased risks of self-reported depression and suicidal 
or self-injurious behaviour in patients prescribed vareni-
cline and bupropion, studies with control groups (such 
as observational cohort studies and experimental study 
designs, mainly RCTs and systematic reviews of RCTs) 
have reported the opposite, and found no evidence of an 
increased risk of these severe neuropsychiatric outcomes 
in patients prescribed these medicines.11 16–18 22–24 
However, there are important limitations associated 
with each of these study designs. First, studies which use 
spontaneous adverse event reports are limited by several 
factors. These include the severity of the adverse event 
(severe adverse events are more likely to be reported than 
less serious events),25 the length of time that the drug has 
been available (adverse events with newer drugs are more 
likely to be reported than events occurring with older 
drugs for the same indication) and media publicity about 
a drug (media reports often lead to increased reporting 
of adverse events to the Yellow Card Scheme, known as 
stimulated reporting).26 27 Second, observational cohort 
studies are prone to the effects of confounding by indi-
cation, which raises concerns about the validity of their 
findings.28 Confounding by indication may occur if an 
observed association between smoking cessation medi-
cines and serious psychiatric events such as suicide is 
explained if the patient case mix differs among those 
taking different smoking cessation medications.11 12 29 In 
two of the earlier cohort studies, varenicline and bupro-
pion were found to be associated with a decreased risk 
of death from all causes compared with NRT11 22; this 
reported protective effect was most likely due to residual 
confounding in the studies.
Experimental studies are less likely to suffer from 
uncontrolled confounding; however, to date, systematic 
reviews and meta-analyses of RCTs have mainly focused 
on comparing the neuropsychiatric safety of varenicline 
monotherapy with placebo.16–18 30 Although this is an 
important research question, patients are unlikely to 
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be prescribed placebo in real-life settings to help them 
quit smoking. Therefore, the neuropsychiatric safety of 
varenicline compared with other smoking cessation drugs 
is likely to be of greater relevance to patients, prescribers 
and regulators. To date, there have been no comprehen-
sive reviews of the neuropsychiatric safety of the smoking 
cessation medicines in relation to each other. In addition, 
there have been no recent cost-effectiveness analyses that 
have fully accounted for adverse events in order to deter-
mine which UK-licensed smoking cessation medicine is 
estimated to be the most cost-effective in UK settings. The 
aim of this study is to determine how smoking cessation 
medicines compare with each other with respect to their 
neuropsychiatric safety in adult smokers. Secondary aims 
include updating the evidence regarding the effective-
ness and cardiovascular safety of these medicines for use 
in a cost-effectiveness analysis.
MeThods and analysIs
criteria for screening studies
Study designs
For the safety network meta-analyses, RCTs of any dura-
tion will be included in addition to observational studies 
with control groups. Uncontrolled observational studies 
(eg, case reports and case series) will be excluded.
For the effectiveness network meta-analyses, we will 
include RCTs of greater than 6 months’ duration in any 
setting, including, but not limited to, primary care prac-
tices, hospitals including inpatient and outpatient clinics, 
universities, workplace clinics, nursing or residential 
homes. Multiarm trials will be included while crossover 
trials, non-randomised trials, quasi-randomised trials and 
interrupted time series analyses will be excluded from the 
effectiveness analyses.
Participants
We will include smokers aged 18 years and over of all 
ethnicities who are seeking to quit smoking using UK-li-
censed smoking cessation therapies. This includes adult 
smokers accessing local authority stop smoking services. 
We will also include smokeless tobacco users. We will 
exclude studies with participants less than 18 years of age 
as varenicline, bupropion and electronic cigarettes are 
only licensed for use in adults in the UK. Non-smoking 
populations will be excluded as well as pregnant and 
breastfeeding women, as varenicline and bupropion are 
not licensed for use in these groups in the UK. If suffi-
cient evidence is identified, we plan to consider the 
following subgroups in all analyses: those with psychiatric 
illness (for example, depression, schizophrenia, bipolar 
disorder, substance misuse), cardiovascular disease (for 
example, peripheral vascular disease, acute coronary 
syndromes and postmyocardial infarction), chronic 
obstructive pulmonary disease, diabetics, heavy smokers 
(defined as people who smoke >20 cigarettes per day) 
and those with previous quit attempts.
Interventions
The smoking cessation medicines that we will assess 
include varenicline, bupropion, nicotine replacement 
therapy and electronic cigarette as monotherapy and in 
combination treatment (eg, varenicline combined with 
NRT, varenicline combined with bupropion and bupro-
pion compared with NRT). For NRT, combinations of 
different formulations given concurrently, for example, 
patch and gum, will also be assessed. Different dosages of 
treatments will also be examined (see online supplemen-
tary appendix 1 which summarise the main pharmacologic 
monotherapies for smoking cessation by formulation and 
dosage using the British National Formulary September 
2016 version (http://www. evidence. nhs. uk/ formulary/ 
bnf/ current) and the MHRA public assessment report for 
the ‘e-Voke’).5 Combination therapies and combinations 
of NRT formulations will also be included in the analyses.
We will exclude trials of alternative and complementary 
therapies (eg, hypnotherapy, acupuncture, aromatherapy 
and herbal therapies) and psychotherapies (unless they 
are included as cotreatment with a pharmacological 
intervention).
outcomes
Safety analysis
The primary composite safety outcome will be serious 
adverse events, defined as events that resulted in death, 
were life threatening, required hospitalisation or resulted 
in significant disability or congenital/birth defect.31 Safety 
outcomes will be grouped under the following headings:
 ► Neuropsychiatric outcomes. The primary 
neuropsychiatric outcomes will include: completed 
suicide, attempted suicide, suicidal ideation, 
depression and seizures. Secondary neuropsychiatric 
outcomes will include: abnormal dreams, aggression, 
anxiety, fatigue, insomnia, irritability, sleep disorders 
and somnolence.
 ► Cardiovascular outcomes. The primary cardiovascular 
outcomes will include: cardiovascular death, non-
fatal myocardial infarction (ie, unstable angina) 
and non-fatal stroke based on the FDA definition.32 
Secondary cardiovascular outcomes will include: 
transient ischaemic attack, congestive heart failure, 
palpitations, arrhythmias and thromboembolism 
(deep vein thrombosis and pulmonary embolism).
Other outcomes will include adverse events such as 
nausea, headache, dry mouth, skin rash and pruritus.
Effectiveness analysis
The primary effectiveness outcome will be sustained 
smoking cessation, defined as abstinence for a 
minimum of 6 months as determined by biochemically 
validated continuous or prolonged abstinence at the 
longest reported time point in intention to treat anal-
yses, as this is the strictest definition of abstinence. As 
we are using data from previous Cochrane reviews of 
smoking cessation medicines,33–36 we have also chosen 
this outcome to be consistent with the definitions used 
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in those reviews. Where these data are not available, we 
will accept point prevalence abstinence and self-report 
quit data. We will treat participants who drop out or are 
lost to follow-up as continuing smokers. We will extract 
information on abstinence at each time point for which 
it is reported to allow a survival model to be estimated 
following the approach used by Chen et al37 and Madan 
et al.38 Data on reductions in smoking, rather than absti-
nence, will not be included. Secondary outcomes will 
include reduction in craving and reduction in with-
drawal symptoms.
search strategy
We will search the following databases: MEDLINE, 
EMBASE, PsycINFO, Web of Science,  Clinicaltrials. gov 
and the Cochrane Databases including the Cochrane 
Database of Systematic Reviews, the Database of Abstracts 
and Reviews of Effectiveness (updated until March 
2015), the Cochrane Central Register of Controlled 
Trials, the NHS Economic Evaluation Database and the 
Health Technology Assessment Database. Searches will 
be conducted with the help of an information specialist 
and will not include any language restrictions. Non-En-
glish language articles will be reviewed by native speakers 
prior to obtaining a full translation. We will also manu-
ally search the reference lists of relevant research articles 
and previous reviews and communicate with authors in 
an attempt to identify unpublished information; in a 
previous study, we had a 75% positive response rate from 
corresponding authors for studies published after 2006.17 
We will also review the literature to identify disutilities 
and costs associated with neuropsychiatric and cardiovas-
cular treatment-related adverse events. Acknowledging 
that we may not find many studies in a smoking cessa-
tion population, we will also search for studies reporting 
disutilities and costs for the same events in other popu-
lations.
To identify studies for the safety network meta-anal-
yses, we will build on the basic search strategy included 
in the cardiovascular network meta-analysis by Mills et 
al39 (see online supplementary appendix 2 for our full 
electronic search strategy for observational studies of 
varenicline in Medline). To identify studies for the effec-
tiveness network meta-analyses, the search strategies 
from four Cochrane reviews33–36 (or updated versions 
where available) will be modified to identify more recent 
trials for inclusion in the current study in addition to 
their previously identified trials. Searches for observa-
tional studies will not be date limited. We will adapt the 
Sheffield economic model30 to incorporate disutilities 
associated with neuropsychiatric and cardiovascular treat-
ment-related adverse events and update model inputs. 
The searches used for the network meta-analyses will be 
rerun with a cost-effectiveness filter to identify studies 
reporting information on utilities, disutilities, resource 
use and costs, which will be used to inform the economic 
evaluation.
study selection and data extraction
Search results will be uploaded to Covidence,40 which 
we will use to screen abstracts and full text and to resolve 
disagreements. Reviewers (MND—all papers, KHT and 
DC—papers equally shared) will independently screen 
abstracts to determine whether full-text reports should 
be obtained. The same reviewers will independently 
identify eligible full-text reports for inclusion. Discrep-
ancies will be resolved by reaching consensus among 
reviewers. We will include a PRISMA diagram41 to 
set out the results of the searches and to indicate the 
number of included and excluded trials. The reasons 
for excluding studies following full-text screening will 
be documented.
Data for studies included following the updated search 
will be extracted by one reviewer (MND) and checked by 
coreviewers (KHT and DC). Information will be collected 
on study design (duration of treatment, description of 
allocation concealment and blinding), study partici-
pants (inclusion and exclusion criteria, country, region 
and population studied), baseline characteristics (eg, 
ethnicity, sex and smoking history), intervention and 
comparison groups (including the smoking cessation 
intervention, whether or not there was cotreatment, 
dosage and formulation), our predefined primary and 
secondary outcomes of interest including measures of 
effectiveness and safety outcomes, losses to follow-up and 
study sponsor. All of the extracted information will be 
summarised in tables. In the event of missing data, we will 
contact authors by email to ask for original data. Authors 
of all newly identified studies will be contacted to verify 
the accuracy of the extracted data.
risk of bias assessment
For RCTs, the Cochrane tool for assessing the risk of 
bias42 will be used to determine whether there is high, 
low or unclear risk of bias in the following domains: 
random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of 
outcome assessment; incomplete outcome data, selective 
outcome reporting and other sources of bias. For obser-
vational studies, we will consider using the risk of bias in 
non-randomised studies of interventions tool43 to deter-
mine whether there is low, moderate, serious or critical 
risk of bias or no information in the following domains: 
confounding, participant selection, intervention classi-
fication, intervention deviations, missing data, outcome 
measurement and selection of the reported result. 
Reviewers (MND—all papers, KHT and DC—papers 
equally shared) will independently assess the risk of bias in 
each of the trials. Discrepancies will be resolved by refer-
ring to the original publication and reaching consensus 
among reviewers. Study authors will be contacted to 
obtain study protocols and additional information that 
may not have been published to aid with assessment of 
the risk of bias.
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data synthesis
Effectiveness outcomes will be summarised as risk ratios. 
Because safety outcomes are rare, we will follow recom-
mendations of Bradburn et al44 and use Peto ORs to 
compare treatment groups although we will also report 
risk differences. All results will be reported including 
95% CIs. The pairwise and network meta-analyses will be 
conducted in a Bayesian framework using OpenBUGS 
software, using code developed by Dias et al.45 We will 
report results of both fixed-effect and random-effect 
meta-analyses; between-study heterogeneity will be quan-
tified using the between-study SD (τ). For each separate 
outcome, we will also construct a network meta-analysis 
(NMA) that will be compared with the pairwise results. For 
the safety outcomes, separate analyses will be conducted 
for RCTs and observational studies. NMA is an extension 
of standard meta-analysis that allows evidence synthesis 
to be performed when there are multiple competing 
interventions available by simultaneously combining 
evidence from all trials reporting that outcome, so long 
as treatments form a connected network.46 Figure 1 shows 
an example of a connected network of seven smoking 
cessation treatments adapted from a Cochrane overview 
of reviews of smoking cessation at 6 months.14 For the 
NMA, combination therapies will be considered separate 
interventions but we will explore models for the effects 
of the component therapies using a main-effect model 
and a two-way interaction model (allowing pairs of thera-
pies to have either a bigger or smaller effect than would 
be expected from the sum of their effects alone). For 
the random-effect NMA, we will assume homogeneous 
between-study variability across studies. We will assess the 
goodness of fit of each model to the data by calculating 
the posterior mean residual deviance. This is defined as 
the difference between the deviance for the fitted model 
and the saturated model, where the deviance measures 
the fit of the model using the likelihood function. The 
Deviance Information Criterion (DIC), which is equal to 
the sum of the posterior mean of the residual deviance 
and the effective number of parameters pD, will be used 
as a basis for model comparison.47 The DIC penalises the 
posterior mean residual deviance (a measure of model 
fit) by the effective number of parameters in the model 
(as measure of complexity) and can therefore be viewed 
as a trade-off between the fit and complexity of the model.
For the pairwise analyses only, and where the number 
of studies allow, we will produce funnel plots.
Assessment of the consistency assumption
Validity of a NMA depends on the assumption that there is 
no effect modification of the pairwise intervention effects 
or, that the prevalence of effect modifiers is similar in the 
different studies. This key assumption has been referred 
to variously as transitivity,48 similarity49 and consistency.50 
We will compile a table of important trial and patient char-
acteristics and visually inspect the ‘similarity’ of factors we 
consider likely to modify treatment effect.
We will visually inspect the network diagram to iden-
tify the extent of potential inconsistency (the number 
of loops) and use model fit and selection statistics to 
informally assess whether it is evident. If inconsistency is 
suspected, we will explore it formally using a ‘node-split-
ting’ approach.50
Health economic modelling
A previously built model30 will be used to evaluate cost-ef-
fectiveness using probabilistic methods and reporting 
fully incremental analyses that meet NICE reference 
case.51 This model has nine health states including those 
most commonly related to smoking. Where data allow the 
model will be adapted to allow more than one attempt at 
quitting and the addition of serious adverse neuropsychi-
atric and cardiovascular events.
Subgroup analyses will be presented as appropriate. 
Sensitivity analyses will be performed including and 
excluding smokeless tobacco users. We will use the 
Grading of Recommendations Assessment, Develop-
ment and Evaluation approach to assess the quality of 
evidence.52Evidence for both effectiveness and safety 
outcomes will be judged for the domains of risk of bias, 
consistency, precision, reporting bias and directness. 
Evidence will be ranked as being of high, moderate, low 
or very low quality.
conclusIon
The proposed systematic review, network meta-analysis 
and cost-effectiveness analysis will address important 
questions about the relative costs or risks and benefits 
of different smoking cessation pharmacotherapies. It 
is expected that the study findings will be incorporated 
into future updates of the new NICE Public Health guid-
ance on Smoking Cessation Interventions and Services, 
a partial update of NICE Public Health guidance on 
Smoking Cessation Services,4 expected to be published 
in November 2017. Critically, we believe that the study 
findings will offer patients, prescribers and regulators 
updated and comprehensive information on the safety 
Figure 1 Network diagram for effectiveness of smoking 
cessation treatments. Adapted from Cahill et al.14  NRT, 
nicotine replacement therapy.
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and effectiveness of these smoking cessation medicines 
that will allow them to make informed decisions when 
evaluating or selecting a pharmacological treatment to 
assist with a quit attempt.
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